• Citer

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

par Devos, Timothy;Geukens, Tatjana;Schauvlieghe, Alexander;Ariën, Kevin K.;Barbezange, Cyril;Cleeren, Myriam;Compernolle, Veerle;Dauby, Nicolas ;Desmecht, Daniel;Grimaldi, David ;Lambrecht, Bart;Luyten, Anne;Maes, Piet;Moutschen, Michel;Romano, Márta ;Seyler, Lucie;Toungouz Nevessignsky, Michel ;Vandenberghe, Katleen;Van Griensven, Johan;Verbeke, Geert;Vlieghe, Erika;Yombi, Jean Cyr;Liesenborghs, Laurens;Verhamme, Peter;Meyfroidt, Geert
Référence Trials, 21, 1
Publication Publié, 2020-11-27

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
Auteur:	Devos, Timothy; Geukens, Tatjana; Schauvlieghe, Alexander; Ariën, Kevin K.; Barbezange, Cyril; Cleeren, Myriam; Compernolle, Veerle; Dauby, Nicolas; Desmecht, Daniel; Grimaldi, David; Lambrecht, Bart; Luyten, Anne; Maes, Piet; Moutschen, Michel; Romano, Márta; Seyler, Lucie; Toungouz Nevessignsky, Michel; Vandenberghe, Katleen; Van Griensven, Johan; Verbeke, Geert; Vlieghe, Erika; Yombi, Jean Cyr; Liesenborghs, Laurens; Verhamme, Peter; Meyfroidt, Geert
Informations sur la publication:	Trials, 21, 1
Statut de publication:	Publié, 2020-11-27
Sujet CREF:	Médecine pathologie humaine
Mots-clés:	Antibodies
	Convalescent plasma
	COVID-19
	Immunity
	SARS-CoV-2
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1745-6215
	info:doi/10.1186/s13063-020-04876-0
	info:pii/4876
	info:scp/85096725354
	info:pmid/33246499